The FDA approved olaparib for the treatment of patients with gBRCAm and HER2-negative metastatic BC who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting, based on the findings of this study. This evidence concerns the gene ERBB2 and breast cancer.